ALTR stock was delisted from NASDAQ on
Mar 25, 2025. You can explore more stocks from
Technology sector on this page.
PSTV Plus Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: PSTV
Price (delayed)
$0.3005
Market cap
$9.83M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.5
Enterprise value
$4,475
Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform
Highlights
The quick ratio has soared by 200% YoY
PSTV's debt has dropped by 99% year-on-year and by 99% since the previous quarter
The EPS has declined by 28% since the previous quarter but it is up by 18% year-on-year
The equity has dropped by 164% since the previous quarter
Plus Therapeutics's net income has shrunk by 130% YoY and by 109% QoQ
Key stats
What are the main financial stats of PSTV
Market
Valuations
Earnings
Shares outstanding
32.72M
Market cap
$9.83M
Enterprise value
$4,475
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0
Revenue
$5.21M
Gross profit
$5.21M
Operating income
-$14.93M
Net income
-$27.12M
EBIT
-$19.67M
EBITDA
-$18.82M
Free cash flow
-$12.29M
Per share
Balance sheet
Liquidity
EPS
-$2.5
EPS diluted
-$2.94
Free cash flow per share
-$0.84
Book value per share
-$1.39
Revenue per share
$0.36
TBVPS
$0.77
Total assets
$12.06M
Total liabilities
$35.7M
Debt
$40,000
Equity
-$23.64M
Working capital
$309,000
Debt to equity
0
Current ratio
1.03
Quick ratio
0.93
Net debt/EBITDA
0.52
Margins
Efficiency
Dividend
EBITDA margin
-361.5%
Gross margin
100%
Net margin
-520.9%
Operating margin
-286.8%
Return on assets
-294.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-1,313.9%
Return on sales
-377.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PSTV stock price
How has the Plus Therapeutics stock price performed over time
Intraday
1.38%
1 week
-13.6%
1 month
-7.68%
1 year
-80.61%
YTD
-73.87%
QTD
-13.6%
Financial performance
How have Plus Therapeutics's revenue and profit performed over time
Revenue
$5.21M
Gross profit
$5.21M
Operating income
-$14.93M
Net income
-$27.12M
Gross margin
100%
Net margin
-520.9%
PSTV's net margin has dropped by 169% year-on-year and by 134% since the previous quarter
Plus Therapeutics's net income has shrunk by 130% YoY and by 109% QoQ
PSTV's operating margin is down by 47% year-on-year and by 14% since the previous quarter
The operating income is down by 26% YoY
Price vs fundamentals
How does PSTV's price correlate with its fundamentals
Growth
What is Plus Therapeutics's growth rate over time
Valuation
What is Plus Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0
The EPS has declined by 28% since the previous quarter but it is up by 18% year-on-year
The equity has dropped by 164% since the previous quarter
The P/S is 56% below the last 4 quarters average of 1.9
PSTV's revenue is down by 14% YoY and by 11% QoQ
Efficiency
How efficient is Plus Therapeutics business performance
The ROA has plunged by 178% YoY and by 72% from the previous quarter
The return on sales has dropped by 138% since the previous quarter and by 100% year-on-year
Dividends
What is PSTV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PSTV.
Financial health
How did Plus Therapeutics financials performed over time
Plus Therapeutics's total assets is 66% lower than its total liabilities
The quick ratio has soared by 200% YoY
Plus Therapeutics's current ratio has soared by 151% YoY
PSTV's debt is 100% greater than its equity
The equity has dropped by 164% since the previous quarter
The debt to equity has surged by 100% since the previous quarter and by 100% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.